Unknown

Dataset Information

Immunotherapy for Non-melanoma Skin Cancer.


ABSTRACT:

Purpose of review

The therapeutic landscape for non-melanoma skin cancer (NMSC) has recently expanded with the development of effective and targeted immunotherapy. Here, we provide an overview of the role of immunotherapy in the management of advanced cutaneous carcinomas.

Recent findings

Several agents were recently U.S. Food and Drug Administration (FDA)-approved for the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma, Merkel cell carcinoma, and basal cell carcinoma. However, recent approvals in tissue-agnostic indications may also benefit other NMSCs including cutaneous adnexal solid tumors with high tumor mutation burdens or microsatellite instability. Furthermore, while FDA-approved indications will likely continue to expand, continued stu

SUBMITTER: Shalhout SZ 

PROVIDER: S-EPMC8395379 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature